ddp ip combined with ag in pdac with peritoneal metastasis

Conditions: Pancreatic Neoplasm

Summary: intraperitoneal (ip) cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis


Eligibility criteria:
inclusion criteria: cohort a patients should meet the following criteria before treatment to be included in the trial: 1. voluntarily participate and sign the informed consent; 2. age ≥18 years old and ≤75 years old, gender is not limited; 3. ecog score ≤2 points; 4. pathological diagnosis of pancreatic adenocarcinoma; 5. advanced pancreatic cancer with intra-abdominal metastasis in imaging assessment, or intra-operative intra-operative findings of intra-abdominal metastasis; 6. the time from the end of adjuvant chemotherapy after surgery is more than 6 months, or they have not received any form of anti-tumor therapy before, including interventional chemoembolization, ablation, radiotherapy, chemotherapy, and molecular targeted therapy; 7. no serious abnormal blood system, heart, lung function and immune deficiency (refer to their respective standards); 8. blood routine indicators: white blood cells ≥3 × 109/l; absolute neutrophil count ≥1.5 × 109/l; platelets ≥100 × 109/l; hemoglobin ≥9 g/dl; 9. blood biochemical indexes: ast (sgot), alt (sgpt) ≤ 2.5 × upper limit of normal (uln); total bilirubin (tbil) ≤ uln; serum creatinine (cre) ≤ 1.5 × uln; 10. coagulation function: prothrombin time (pt), international normalized ratio (inr) ≤ 1.5 × uln; 11. able to comply with research visit plans and other protocol requirements. inclusion criteria (cohort b) patients should meet the following criteria before treatment to be included in the trial: 1. voluntarily participate and sign the informed consent; 2. age ≥18 years old and ≤75 years old, gender is not limited; 3. ecog score ≤2 points; 4. pathological diagnosis of pancreatic adenocarcinoma; 5. malignant ascites with positive peritoneal cytology or laparoscopic exploration processed. 6. at least one systemic chemotherapy has been used; 7. no serious abnormal blood system, heart, lung function and immune deficiency (refer to their respective standards); 8. blood routine indicators: white blood cells ≥3 × 109/l; absolute neutrophil count ≥1.5 × 109/l; platelets ≥100 × 109/l; hemoglobin ≥9 g/dl; 9. blood biochemical indexes: ast (sgot), alt (sgpt) ≤ 2.5 × upper limit of normal (uln); total bilirubin (tbil) ≤ uln; serum creatinine (cre) ≤ 1.5 × uln; 10. coagulation function: prothrombin time (pt), international normalized ratio (inr) ≤ 1.5 × uln; 11. able to comply with research visit plans and other protocol requirements. exclusion criteria: patients were excluded from the study if they met any of the following criteria: 1. associated with other systemic malignant tumors; 2. single kidney, deformed kidney or poor renal compensation; 3. have used any other study drug within 7 days before chemotherapy; 4. patients with central nervous system disease, mental illness, unstable angina pectoris, congestive heart failure, severe arrhythmia and other serious diseases that cannot be controlled; 5. there is a history of allergy to the study drug or drugs of similar structure; 6. patients who are using and require long-term use of warfarin anticoagulation.